congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Dato-DXd
ACoP15 | November 10-13, 2024
Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
Poster
R-DXd
ACoP15 | November 10-13, 2024
Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors
Poster
Valemetostat
ACoP15 | November 10-13, 2024
Population pharmacokinetic and exposure-response modelling analyses to support valemetostat dose recommendations in relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) patients
Poster
DS-6157
ACoP15 | November 10-13, 2024
Population pharmacokinetics and exposure–safety of DS-6157 in patients with advanced gastrointestinal stromal tumor